期刊文献+

宫颈癌肿瘤标志物的研究进展 被引量:2

Research on Markers of Cervical Cancer
原文传递
导出
摘要 宫颈癌相关肿瘤标志物是宫颈癌组织和细胞由于癌基因及其产物的异常表达所产生的抗原和生物活性物质,包括蛋白质、酶、激素、癌基因产物等。近年来肿瘤标志物成为肿瘤基础和临床应用的一个十分活跃的领域。其对宫颈癌的辅助诊断、判别类型、估计预后、评价疗效、定位诊断、靶向治疗等均具有重要指导意义。目前与宫颈癌有关的生物标记物有数十种,包括人乳头状瘤病毒感染、细胞周期调节蛋白、细胞凋亡相关因子等。随着研究的深入,这些生物标记物在临床上已显示出广阔的应用前景。 Tumor markers are bioactive substance and antigen produced by cervical cancer tissue and cell because of oncogene abnormal expression including protien,enzyme and hormone et al.In recent years,tumor marker has been one of the most active areas in basic research and clinical investigation of oncology.A variety of tumor markers have been shown to have potential applications in accessory diagnosis,clinicaltyping,prognosis,and therapeutic respons and target therapy of cervical cancer.Now tens of markers reported are related to cervical cancer,including HPV infection,cell cycle regulatory protein,apoptosis,and other related factors.With the in-depth study,these markers in clinical practice has shown broad prospects.
出处 《现代生物医学进展》 CAS 2010年第9期1777-1779,共3页 Progress in Modern Biomedicine
关键词 宫颈癌 肿瘤标志物 KI-67 AI cervical cancer tumor markers KI-67 AI
  • 相关文献

参考文献2

二级参考文献16

  • 1刘颖,林新生,刘慧.细胞凋亡和P53、PCNA表达在宫颈癌的研究[J].临床肿瘤学杂志,2004,9(5):461-463. 被引量:8
  • 2郭昕.c-myc和p53蛋白在宫颈癌组织中的表达及临床意义[J].局解手术学杂志,2005,14(3):147-148. 被引量:7
  • 3Ferrandina G, Macchia G, Legge F, et al. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy : association with pathological response to treatment and clinical outcome [J]. Oncology, 2008,74(1-2) :42-49.
  • 4Ohno T, Nakayama Y, Nakamota S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix [ J ]. Cancer, 2003,97 : 3114-3120.
  • 5Forni F, Ferrandina G, Deodato F, et al. Squamous cell carcinoma in follow-up cervical cancer treated with radiotherapy : evaluation of cost-effectiveness [J]. Int J Radiat Oncal Biol Phys, 2007,69(4) : 1145-1149.
  • 6Hirakawa M, Nagai Y, Inamine M, et al. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy [J]. Gynecol Oncol, 2005,108( 1 ) : 126-129.
  • 7Micke O, Prott FJ, Schafer U, et al. The impact of squamous cell carcinoma(SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer [J]. Anticancer Res, 2000,20 (6D):5113-5115.
  • 8Hong JH, Tsai CS, Chang TC, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy [J]. Int J Radiat Oncol Biol Phys, 2004,60( 1 ) : 249-257.
  • 9Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival [J]. Cancer, 2007,110(8) : 1738-1744.
  • 10Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F- fluorodeoxyglucose(FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma [J]. Anticancer Res, 2003,23(4) :3263-3272.

共引文献13

同被引文献37

  • 1Parkin DM,Bray F,Ferlay J,et al.Global Cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 2Kamangar F,Dores GM,Anderson WF.Patterns of cancer inci-dence,mortality,and prevalence across five continents:definingpriorities to reduce cancer disparities in different geographicregions of the world[J].J Clin Oncol,2006,24(14):2137-2150.
  • 3Ogawa E,Okuyama R,Ikawa S,et al.p51/p63 inhibits ultravioletB-induced apoptosis via Akt activation[J].Oncogene,2008,27(6):848-856.
  • 4Shai A,Pitot HC,Lambert PF.p53 loss synergizes with estrogenand papillomaviral oncogenes to induce cervical and breast cancers[J].Cancer Res,2008,68(8):2622-2631.
  • 5Malinowski DP.Multiple biomarkers in molecular oncology.Ⅰ.Molecular diagnostics applications in cervical cancer detection[J].Expert Rev Mol Diagn,2007,7(2):117-131.
  • 6Balasubramanian A,Hughes J,Mao C,et al.Evaluation of anELISA for p16INK4a as a screening test for cervical cancer[J].Cancer Epidemiol Biomarkers Prev,2009,18(11):3008-3017.
  • 7Lakshmi S,Rema P,Somanathan T.p16ink4a is a surrogate markerfor high-risk and malignant cervical lesions in the presence ofhuman papillomavirus[J].Pathobiology,2009,76(3):141-148.
  • 8Yildi IZ,Usubütün A,Firat P,et al.Efficiency of immunohisto-chemical p16 expression and HPV typing in cervical squamousintraepithelial lesion grading and review of the p16 literaturepathology[J].Pathol Res Pract,2007,203(6):445-449.
  • 9Ordi J,Garcia S,del Pino M,et al.p16INK4a immunostainingidentifies occult CIN lesions in HPV-positive women[J].Int JGynecol Pathol,2009,28(1):90-97.
  • 10Tan GC,Norlatiffah S,Sharifah NA,et al.Immunohistochemicalstudy of p16INK4A and survivin expressions in cervical squamousneoplasm[J].Indian J Pathol Microbiol,2010,53(1):1-6.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部